Skip to main content

Table 1 Associations between LZTS2 promoter methylation and LSCC patient clinicopathological characteristics

From: LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma

Variable Number Mean ± SD P value
Gender
 Female 4 20.11 ± 6.39 0.364
 Male 92 27.37 ± 15.80
Age
 ≥ 60 49 24.05 ± 14.15 0.995
 < 60 47 27.07 ± 17.09
Smoking behavior
 Yes 78 28.57 ± 15.94 0.049
 No 18 20.56 ± 12.21
Histological classification
 Well 45 27.98 ± 15.35 0.590
 Moderately/poorly 51 26.25 ± 15.88
T classification
 T 1 + 2 57 23.26 ± 13.47 0.003
 T 3 + 4 39 32.62 ± 12.90
Clinical stage
 Stage I + II 45 22.44 ± 11.64 0.005
 Stage III + IV 51 31.14 ± 17.48  
Lymph metastasis
 Yes 33 32.85 ± 18.62 0.019
 No 63 24.03 ± 12.87
  1. LZTS2 promoter methylation levels were significantly elevated in advanced stage and advanced T classified patients, in patients who were smokers, as well as cases with lymph node metastasis. Italicized entries indicate statistical significance